

NEXPLANON (etonogestrel)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

NEXPLANON is a progestin implant indicated for use by women to prevent pregnancy/

Authorization: for contraception

Dosing: a single implant containing 68mg of the progestin etonogestrel inserted subdermally in the upper arm and replaced every three years

PRECAUTIONS: There are numerous precautions listed in the product literature, which should be consulted for details (e/g/ ectopic pregnancy, PID/sepsis, perforation, device failure, bleeding, glucose intolerance)

DRUG INTERACTIONS: Drugs or herbal products that induce enzymes that metabolize progestins (e/g/ CYP3A4) may decrease effectiveness (e/g/ barbiturates, carbamazepine, oxcarbazepine, phenytoin, St/ John's wort)/ Variable changes in serum concentrations when used with protease inhibitors and other drugs used to treat HIV infection

REFERENCES

1. National Institute for Health and Clinical Excellence/ *NICE Clinical Guidelines CG30/ Long Acting Reversible Contraception: The Effective And Appropriate Use Of Long-Acting Reversible Contraception*/ London: NICE, 2005/
2. Hohmann H, Creinin M/ The contraceptive implant/ *Clin Obstet Gynecol* 2007; **50**(4): 907–917/
3. Graesslin O, Korver T/ The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience/ *Eur J Contracept Reprod Health Care* 2008; **13**(Suppl/ 1): 4–12/
4. Power J, French R, Cowan F/ Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy/ *Cochrane Database Syst Rev* 2007; **3**: CD001326/

5. Funk S, Miller M, Mishell D, *et al*/ Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel/ *Contraception* 2005; **71**(5): 319–326/
6. Otero Flores JB, Balderas ML, Bonilla MC, Vázquez-Estrada L/ Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant/ *Int J Gynaecol Obstet* 2005; **90**(3): 228–33/

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
 Date Approved by P&T Committee: 1/27/15
 Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/26/16
 Date Reviewed/No Updates: 1/24/17 by C/ Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/24/17
 Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/23/18
 Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
 Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check ESI